title: Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration.
abstract: Prion diseases are characterized by accumulation of misfolded protein, gliosis, synaptic dysfunction, and ultimately neuronal loss. This sequence, mirroring key features of Alzheimer disease, is modeled well in ME7 prion disease. We used iTRAQ(TM)/mass spectrometry to compare the hippocampal proteome in control and late-stage ME7 animals. The observed changes associated with reactive glia highlighted some specific proteins that dominate the proteome in late-stage disease. Four of the up-regulated proteins (GFAP, high affinity glutamate transporter (EAAT-2), apo-J (Clusterin), and peroxiredoxin-6) are selectively expressed in astrocytes, but astrocyte proliferation does not contribute to their up-regulation. The known functional role of these proteins suggests this response acts against protein misfolding, excitotoxicity, and neurotoxic reactive oxygen species. A recent convergence of genome-wide association studies and the peripheral measurement of circulating levels of acute phase proteins have focused attention on Clusterin as a modifier of late-stage Alzheimer disease and a biomarker for advanced neurodegeneration. Since ME7 animals allow independent measurement of acute phase proteins in the brain and circulation, we extended our investigation to address whether changes in the brain proteome are detectable in blood. We found no difference in the circulating levels of Clusterin in late-stage prion disease when animals will show behavioral decline, accumulation of misfolded protein, and dramatic synaptic and neuronal loss. This does not preclude an important role of Clusterin in late-stage disease, but it cautions against the assumption that brain levels provide a surrogate peripheral measure for the progression of brain degeneration.
authors.affiliation: From the Centre for Biological Sciences and.
authors.forename: Ayodeji A
authors.initials: AA
authors.lastname: Asuni
authors.forename: Bryony
authors.initials: B
authors.lastname: Gray
authors.forename: Joanne
authors.initials: J
authors.lastname: Bailey
authors.forename: Paul
authors.initials: P
authors.lastname: Skipp
authors.forename: V Hugh
authors.initials: VH
authors.lastname: Perry
authors.forename: Vincent
authors.initials: V
authors.lastname: O'Connor
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001253:Astrocytes / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers / Q000378:metabolism; D051152:Clusterin / Q000096:biosynthesis*; D004195:Disease Models, Animal; D005260:Female; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D051379:Mice; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D017096:Prion Diseases / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D020543:Proteome / Q000096:biosynthesis*
chemical_list: D015415:Biomarkers; C495243:Clu protein, mouse; D051152:Clusterin; D009419:Nerve Tissue Proteins; D020543:Proteome
keywords: Astrocytes; ME7; Mass Spectrometry (MS); Neurobiology; Neurodegeneration; Prion; Prions; iTRAQ; mRNA